Companies

Lupin recalls 35,928 bottles of generic antibiotic drug in the US

PTI New Delhi | Updated on August 02, 2020 Published on August 02, 2020

Drug major Lupin is recalling 35,928 bottles of a generic antibiotic drug in the US market following unfavourable result in retention samples, the US health regulator said in a report.

Per the latest Enforcement Report of the US Food and Drug Administration (USFDA), the Mumbai-based company is recalling Cefdinir for oral suspension USP, 250 mg/5mL, packaged in 60 ml bottles.

The lot has been manufactured at Lupin’s Mandideep (Madhya Pradesh) manufacturing facility, and then supplied to company’s Baltimore-based arm, Lupin Pharmaceuticals Inc, which has initiated the country-wide recall on July 2.

Per the USFDA, the company is recalling the specific lot due to “out-of-specification (OOS) result observed in an assay test of retention samples.” Cefdinir is an antibiotic used to treat pneumonia, otitis media, strep throat, and cellulitis.

The ongoing voluntary recall has been classified as class II recall.

A class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. The company did not elaborate if the product is also sold in India. A mail sent to the company in this regard remained unanswered.

According to an earlier report of the regulator, the Mumbai-based firm is also in the process of recalling 4,92,858 bottles of Metformin Hydrochloride extended-release tablets in 500 mg and 1,000 strengths due to possibility of the affected lot containing cancer causing nitrosodimethylamine (NDMA) above the acceptable intake limit.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on August 02, 2020
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.